TITLE

Negative screening for 12 rare LRRK2 pathogenic variants in a cohort of Nigerians with Parkinson's disease

AUTHORS

Mie Rizig, Oluwadamilola O. Ojo, Alkyoni Athanasiou-Fragkouli, Osigwe P. Agabi,
Olajumoke O. Oshinaike, Houlden H, Njideka U. Okubadejo

Abstract

Mutations in the leucine-rich repeat kinase 2 (*LRRK2*) gene are the most commonly identified genetic variants in familial and sporadic Parkinson's disease (PD). Over three hundred *LRRK2* variants have been described in the literature, of which at least 17 have a confirmed or probable pathogenic role in PD. The distribution of these rare pathogenic variants has been shown to be different among ethnic groups including Caucasians, Latin Americans and East and South Asians. However, to date no PD-related *LRRK2* pathogenic variant has been described in persons of black African ancestry within or outside Africa. We previously reported that the *LRRK2* *p.gly2019ser* mutation was not found in 126 PD patients and 55 controls from Nigeria. Using Kompetitive Allele-Specific Polymerase chain reaction (KASP), we screened a new cohort of 92 Nigerians with PD and 210 healthy ethnically matched controls for 12 rare *LRRK2* variants (which have been shown to be pathogenic in other ethnic populations) including: *p.gly2019ser*, *p.Arg1441His*, *p.Gly2385Arg*, *p.Ala419Val*, *p.Arg1628Pro*, *p.Pro755Leu*, *p.Ile2020Thr* and *Tyr1699Cys*. All 12 rare variants were absent in PD patients and controls from this cohort. These results endorse our previous findings and confirm that rare *LRRK2* pathogenic variants reported in Caucasians, Asians and persons of mixed ancestry are absent in West Africans. Applying next generation sequencing technologies in future studies is necessary to explore possible novel *LRRK2* variants indigenous to black Africans.

Key words

Parkinson's disease, African, black, Nigeria, *LRRK2*, genetic, genes

Introduction

The current concept of Parkinson's disease (PD) is that of a complex disease that results from a combination of genetic and environmental influences. Although PD is the fastest growing neurological disorder and the second most prevalent neurodegenerative disease in Africa, very little is known about the genetic contributors to PD in black Africans. (1, 2) The urgent need to expand the exploration of PD genetics research in Africa is justified by the fact that advances in gene discovery initiatives that occurred in the last twenty years are currently being translated to drug treatments and other preventive and diagnostic interventions. (3) The relevance of these developments to black Africans will depend on understanding the genetic architecture of PD within the continent's indigenous populations.

Mutations in the leucine-rich repeat kinase 2 (*LRRK2*) gene are the most commonly identified genetic variants in familial and sporadic PD. To date, over three hundred PD-related *LRRK2* variants have been described. (4) The spectrum of these variants ranges from rare mutations with very large effects (i.e. fully or highly penetrant) to genetic variants exerting only modest effects but that are relatively common in the general population. (5) At least 17 rare *LRRK2* variants have demonstrated convincing evidence of pathogenicity in PD based on association, disease segregation and functional studies. (6 – 8) The frequency of these rare variants differs significantly between ethnic groups, suggesting population specific founder effects. (7) For instance, the *p.gly2019ser* - the most commonly reported *LRRK2* PD causing variant worldwide - has its highest prevalence in PD in North Africa, where it is reported to occur in 30-41% of familial and 30-39% of apparently sporadic PD respectively. (9) The *p.gly2019ser* contributes to a lesser extent to PD risk in Caucasians (1-4%) and west Asians (1%). (10, 11) The *p.gly2019ser* has not been reported in East Asians and black Africans. (6, 11, 12) Three rare *LRRK2* variants (*p.Gly2385Arg*, *p.Ala419Val* and *p.Arg1628Pro*) were repeatedly reported to increase PD risk in East

Asians and have been consistently absent in Caucasian PD cohorts. (7) On the other hand, three rare *LRRK2* variants known to occur within the same codon (*p.Arg1441Gly*, *p.Arg1441Cys* and *p.Arg1441His*) were reported in persons with PD of Caucasian and East Asian origins. (6) Interestingly, the *LRRK2 p.Arg1441Gly* is almost exclusively restricted to the Spanish Basque region with only five reported probands outside Northern Spain. (13 – 18) Similarly, the *p.Ile2020Thr* substitution was only identified in three Japanese pedigrees. (19, 20)

To date no *LRRK2* pathogenic variant has been identified in PD amongst persons of black African ancestry within or outside Africa. A few studies including two from our group in Nigeria, one in Zambia, one in Ghana and several in South Africa have investigated the *LRRK2* PD pathogenic variants in Sub-Saharan Africa. (21-30) In the present report, we expand on our previous enquiry which focused only on *LRRK2 p.gly2019ser* in Nigeria, to explore the frequency of 12 pathogenic rare PD-associated *LRRK2* variants including the *p.gly2019ser* in a new cohort of 92 Nigerians with PD and 210 ethnically matched controls.

Materials and Methods

This study was approved by the Health Research Ethics Committee of the Lagos University Teaching Hospital, Idi Araba, Lagos State, Nigeria (Ethics approval # ADM/DCST/HREC/366) and the ethics committee of the University College London and the National Hospital for Neurology and Neurosurgery, London, United Kingdom (Ethics approval # 07/Q0512/26). Written informed consent was obtained from all participants.

Participant recruitment, diagnostic ascertainment and clinical evaluation

Persons with PD were recruited from the Movement Disorders Clinic at the Lagos University Teaching Hospital as part of an ongoing study of the genetics of PD in Nigeria. Case ascertainment was based on the United Kingdom Parkinson Disease Brain Bank (UKPDBB) clinical criteria applied by a Movement Disorders neurologist. (31) Controls were unrelated community volunteers without clinically evident neurological symptoms or signs, otherwise healthy, and matched by gender and local ethnicity. Baseline demographics including age at study, age at onset of PD, gender, family history of PD, and PD stage on the Hoehn and Yahr scale were documented. Clinical characteristics of the cohort are summarized using appropriate descriptors including mean $\pm$ standard deviation (SD) for continuous variables and % frequency for categorical variables. Statistical analysis was conducted using the Statistical Package for Social Sciences (SPSS)® version 21.0 software.

Genetic analysis

DNA was extracted from venous whole blood samples (10mls) using standard protocols. Genotyping was performed using Kompetitive Allele-Specific Polymerase chain reaction (PCR) assay (KASP™, LGC Genomics. Herts, UK) as described previously. (22, 32) 12

single nucleotide polymorphisms (SNPs) were selected for genotyping namely: rs34637584 (*p.Gly2019Ser*), rs34995376 (*p.Arg1441His*), rs74163686 (*p.Asn1437His*), rs35870237 (*p.Ile2020Thr*), rs35801418 (*p.Tyr1699Cys*), rs34410987 (*p.Pro755Leu*), rs34778348 (*p.Gly2385Arg*), rs281865052 (*p.Met1869Val*), rs34594498 (*p.Ala419Val*), rs33949390 (*p.Arg1628Pro*), rs35808389 (*p.Leu1114Leu*), rs34805604 (*p.Ile1122Val*). SNPs selection was based on evidence of pathogenicity in PD through replicated association studies, excellent disease segregation data and (or) functional data, in addition to the availability of a validated KASP assay for each SNP. Pathogenic evidence was confirmed by screening ClinVar and MDSGene databases. (33, 34) SNP rs33939927 encoding for *p.Arg1441Gly/Cys/Ser* was originally considered for genotyping but later on deemed unsuitable for the KASP assay due to its close proximity to rs34995376 (*p.Arg1441His*) and its tri-allelic nature. Genotyping results were visualized with SNP Viewer software (version 1.99, Hoddesdon, UK). Genotypes were examined for deviation from Hardy-Weinberg equilibrium using Chi-square test.

Results

92 participants with PD (76.1% male) and 210 controls (66.7% male) were included. All participants were native Nigerians, predominantly of Yoruba ethnicity (62 PD (67.4%) and 172 controls (81.9%)). Mean age at study (years) was 62.1 ± 9.2 in PD and 64.5 ± 6.7 in controls. 5 (5.4 %) and 20 (21.7%) had early onset PD starting before age 40 and 50 respectively. Positive family history of PD was documented in 9 PD (9.8%) including only 3 with early onset disease. Clinical characteristics of the cohort are summarised in Table 1.

KASP assay performed very well, with 99-100% call rates achieved with clear genotyping clusters and no ambiguous calls for all 12 SNPs. Genotyping calls including uncalled samples from all SNPs are listed in Supplementary Table 1. *LRRK2* pathogenic alleles were absent for all the 12 genotyped SNPS in all PD and control participants. Allelic frequencies for all SNPs were in Hardy-Weinberg equilibrium ($P = 1$). Details of the 12 SNPs included in this study and their genotyping results are shown in Table 2.

Discussion

In this study we expanded on our previous enquiry regarding the role of rare *LRRK2* variants in PD in persons of sub-Saharan African black ancestry by exploring a third cohort from Nigeria. We used an efficient, economical and accurate method – the Kompetitive Allele-Specific Polymerase chain reaction (PCR) assay (KASP) – to screen a new cohort of 92 PD patients and 210 controls for five rare variants classified as definitely pathogenic in Europeans, Asians and patients of mixed ancestries: *p.Gly2019Ser*, *p.Arg1441His*, *p.Asn1437His*, *p.Ile2020Thr* and *p.Tyr1699Cys*. In addition we screened for variants known to be pathogenic in East Asians: *p.Gly2385Arg*, *p.Ala419Val* and *p.Arg1628Pro*. We added four extremely rare variants to the screening: *p.Pro755Leu*, *p.Leu1114Leu*, *p.Ile1122Val* and *p.Met1869Val*. These variants are classified as pathogenic and (or) probably pathogenic. All 12 rare variants were found to be absent in all participants.

The last two decades have witnessed genetic discoveries which have transformed our understanding of PD pathology and pathogenesis. Mutations in the *LRRK2* gene are among the most important findings in PD genetics. Pathogenic mutations in *LRRK2* enhance the enzymatic activity of the *LRRK2* protein, and drugs which inhibit or regulate this activity could have a neuroprotective effect in PD. (6) The genetic contribution of the *LRRK2* to PD pathogenesis in Sub-Saharan Africa remains unknown, and evidence from familial and case control studies in genetically diverse populations demonstrates that *LRRK2* pathogenic variants - with the exception of the *p.Gly2019Ser* - are ethnically or geographically specific. (7)

In the last 12 years a handful of studies screened for *LRRK2* variants in PD cohorts from Nigeria, Zambia, South Africa and Ghana. Yonova-Doing et al used Sanger sequencing to screen for pathogenic variants in *LRRK2* exons 29 to 48 in thirty-eight Zambian patients with idiopathic PD, one patient with juvenile-onset levodopa-responsive atypical

Parkinsonism, and 181 ethnically matched controls. (28) The whole *LRRK2* coding region (51 exons) was sequenced in the familial patients and those with onset <55 years (n = 22). No pathogenic variant was identified in any of the Zambian patients and controls although one novel missense variant with unconfirmed pathogenicity (*p.Ala1464Gly*) was reported in one person with apparently idiopathic PD. Cilia et al screened exons 31 (including *p.Gly2019Ser* and *p.Ile2020Thr*) and exon 41 (including, *p.Arg1441gly/Cys/His*) in 54 PD and 46 controls from Ghana, but no pathogenic variant was identified. (29) Data from the studies from South Africa collectively included about 177 PD patients of black South African origin, 14 Nigerians and no controls, although it is unclear if some of the patients were investigated more than once. A combination of methods including multiplex ligation-dependent probe amplification (MLPA), high-resolution melt (HRM), quantitative real time PCR and targeted sequencing panels were used. In all 191 black African ancestry patients, no *LRRK2* pathogenic variant was identified. (29) In 2008, our group applied Sanger sequencing to screen for pathogenic mutations in exons 31 and 41 of the *LRRK2* gene in a cohort of 57 Nigerians with PD and 51 matched controls, and in 2018 we further screened for the *p.Gly2019Ser* in a second cohort of 126 Nigerian PD patients and 55 controls. (21, 22) We were unable to identify any pathogenic variants in both cohorts. In total, our group has screened 275 Nigerians with PD and 316 controls, and no pathogenic variants of *LRRK2* have as yet been demonstrated.

The main limitation of this study is the use of a targeted screening methodology (KASP assay) which screened for 12 variants but could not exclude other possible rare mutations such as *p.Arg1441Gly/Cys/Ser*, *p.Glu923His*, *p.Lys616Arg*, *p.Arg151Glu* or identify new pathological variants specific to the cohort. We acknowledge the modest size of the cohort and the importance of explorations including larger samples.

In conclusion, our study corroborates previous reports from our group and others in Sub-Saharan Africa and recaps that rare *LRRK2* variants reported in PD from other populations are as yet unidentified in black Africans. As recently reiterated, only a fraction of likely genetic risk for PD (including that attributable to *LRRK2*) has been identified, and conducting studies in diverse populations such as persons with black African ancestry may hold the key to further unravelling discoveries that will enhance the translation and application of the knowledge into therapies for PD. (35) In order to achieve this and understand the role of *LRRK2* in PD in Africa, resources need to be committed to build sufficiently powered large cohorts and employ advanced sequencing technologies to investigate the role of rare *LRRK2* and other PD-related genetic native to black Africans.

Table 1. Clinical characteristics of Parkinson's disease and control participants

Parameter	Parkinson's disease n = 92	Controls n = 210
Gender distribution (<i>n</i> , %)		
• Female	22 (23.9%)	70 (33.3%)
• Male	70 (76.1%)	140 (66.7%)
Age at study, years (mean $\pm$ SD)	62.1 $\pm$ 9.2	64.5 $\pm$ 6.7
Ethnic group of origin (<i>n</i> , %)		
• Yoruba	62 (67.4%)	172 (81.9%)
• Igbo	19 (20.7%)	23 (11.0%)
• Others*	11 (12%)	15 (7.1%)
Age at onset, years (mean $\pm$ SD)	58.8 $\pm$ 9.4	NA
• Young onset PD (< 40 years) (<i>n</i> , %)	5 (5.4%)	NA
• Early onset PD (< 50 years) (<i>n</i> , %)	20 (21.7%)	NA
Family history of Parkinson disease (<i>n</i> , %)	9 (9.8%)	NA
• Young onset PD (< 40 years, n=5) (<i>n</i> , %)	0 (0%)	
• Early onset PD (< 50 years, n=20) (<i>n</i> , %)	3 (15.0%)	
Hoehn and Yahr Stage (Median)	2.0	NA

Footnote:

SD – standard deviation; YOPD – young onset PD; EOPD – early onset PD

*Others – other Nigerian ethnic groups (n=26 all participants; Ishan/Esan/Bini/Urhobo/Other Edo – 9; Ibibio/Anang/Efik – 5; Igbirra – 3; Itsekiri – 2; Ukwani – 2; Hausa – 1; Idoma – 1; Iyalla – 1; Nupe – 1; Tiv – 1.)

**Table 2. Description and genotyping results of the 12 *LRRK2* rare SNPs screened in the 92 Nigerian PD patients
and 210 controls**

SNP Allele Position ⁽¹⁾	Protein	Type Mutation	Ethnic population at risk of PD	SNP alternative allele frequencies as reported in the Allele Frequency Aggregator (ALFA) ⁽²⁾⁽³⁾						Nigerian cohort
				European	African	Asian	Latin American	Others	Total	Genotype
rs34594498 C>T chr12:40252984	<i>p.Ala419Val</i>	Missense, pathogenic	East Asian	0.00026	0.000	0.012	0.000	0.0007	0.00033	CC (PD 92, Control 210)
rs34410987 C>T chr12:40283897	<i>p.Pro755Leu</i>	Missense, possibly pathogenic	East Asians	0.00000	0.000	0.018	0.00	0.0003	0.00005	CC (PD 92, Control 210)
rs33949390 G>A,C,T chr12:40320043	<i>p.Arg1628His</i> <i>p.Arg1628Pro</i> <i>p.Arg1628Leu</i>	Missense, probably pathogenic	East Asian	A=0.0000, C=0.0005	A=0.000, C=0.000	A=0.00, C=0.05	A=0.000, C=0.000	A=0.0000, C=0.0000	A=0.00000, C=0.00063	GG (PD 92, Control 209)
rs35801418 A>G chr12:40321114	<i>p.Tyr1699Cys</i>	Missense, pathogenic	European South Korean	0.00005	0.00	0.00	0.00	G=0.0000	0.00004	AA (PD 92, Control 210)
rs34637584 G>A chr12:40340400	<i>p.Gly2019Ser</i>	Missense, pathogenic	European, West Asian and mixed populations	0.00118	0.001	0.000	0.000	A=0.0020	0.00125	GG (PD 92, Control 210)
rs35870237 T>C chr12:40340404	<i>p.Ile2020Thr</i>	Missense, pathogenic	East Asian (Japan/Taiwan)	0.000	0.000	0.000	0.000	C=0.0003	0.00004	TT (PD 92, Control 208)
rs34778348 G>A chr12:40363526	<i>p.Gly2385Arg</i>	Missense, pathogenic	East Asian	0.000	0.000	0.038	0.003	0.0004	0.00013	GG (PD 92, Control 209)
rs35808389 A>G chr12:40298488	<i>p.Leu1114Leu</i>	Synonymous pathogenic	Europeans	0.00017	0.000	0.000	0.000	0.000	0.00015	AA (PD 92, Control 210)
rs34805604 A>G chr12:40299125	<i>p.Ile1122Val</i>	Missense, pathogenic	European	0.00005	0.000	0.000	0.000	0.000	0.00004	AA (PD 92, Control 208)

rs74163686 A>C chr12:40309225	<i>p.Asn1437His</i>	Missense, pathogenic	European	0.000	0.000	0.000	0.000	0.000	0.000	AA (PD 92, Control 210)
rs34995376 G>A chr12:40310435	<i>p.Arg1441His</i>	Missense, pathogenic	European	0.00004	0.000	0.000	0.000	0.000	0.00003	GG (PD 92, Control 210)
rs281865052 A>G chr12:40323255	<i>p.Met1869Val</i>	Missense, pathogenic	European (Norway)	0.000	0.000	0.000	0.000	0.000	0.000	AA (PD 92, Control 208)

Footnote: (1) Position is based on GRCh38. (2) *L. Phan, Y. Jin, H. Zhang, W. Qiang, E. Shekhtman, D. Shao, D. Revoe, R. Villamarin, E. Ivanchenko, M. Kimura, Z. Y. Wang, L. Hao, N. Sharopova, M. Bihan, A. Sturcke, M. Lee, N. Popova, W. Wu, C. Bastiani, M. Ward, J. B. Holmes, V. Lyoshin, K. Kaur, E. Moyer, M. Feolo, and B. L. Kattman. "ALFA: Allele Frequency Aggregator." National Center for Biotechnology Information, U.S. National Library of Medicine, 10 Mar. 2020. Available at: www.ncbi.nlm.nih.gov/snp/docs/gsr/alfa/.* (3) Frequencies are correct for June 2020.

Supplementary Table 1. Genotype calls for all 12 LRRK2 SNPs included in the study

REFERENCES

1. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* 2019;18(5):459-480.
2. GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* 2018;17(11):939-953.
3. Poewe W, Seppi K, Marini K, Mahlknecht P. New hopes for disease modification in Parkinson's Disease. *Neuropharmacology.* 2020;171:108085.
4. Clinvarminer. Variants in gene LRRK2. Available at <https://clinvarminer.genetics.utah.edu/variants-by-gene/LRRK2>. Accessed 18/06/2020.
5. Lill CM. Genetics of Parkinson's disease. *Mol Cell Probes.* 2016;30(6):386-396.
6. Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. *Nat Rev Neurol.* 2020;16(2):97-107.
7. Shu L, Zhang Y, Sun Q, Pan H, Tang B. A Comprehensive Analysis of Population Differences in LRRK2 Variant Distribution in Parkinson's Disease. *Front Aging Neurosci.* 2019;11:13.
8. Houlden H, Singleton AB. The genetics and neuropathology of Parkinson's disease. *Acta Neuropathol.* 2012;124(3):325-338.
9. Benamer HTS, de Silva R. LRRK2 G2019S in the North African population: a review. *Eur Neurol.* 2010;63:321–325
10. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. *Lancet Neurol.* 2008;7(7):583-590

11. Monfrini E, Di Fonzo A. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease. *Adv Neurobiol.* 2017;14:3-30.
12. Ren C, Ding Y, Wei S, et al. G2019S Variation in LRRK2: An Ideal Model for the Study of Parkinson's Disease?. *Front Hum Neurosci.* 2019;13:306.
13. Deng H, Le W, Guo Y, et al. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. *J Neurol Sci.* 2006;251(1-2):102-106.
14. González-Fernández MC, Lezcano E, Ross OA, et al. Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. *Parkinsonism Relat Disord.* 2007;13(8):509-515.
15. Mata IF, Hutter CM, González-Fernández MC, et al. Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. *Neurogenetics.* 2009;10(4):347-353.
16. Yescas P, López M, Monroy N, et al. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease. *Neurosci Lett.* 2010;485(2):79-82.
17. Cornejo-Olivas M, Torres L, Velit-Salazar MR, et al. Variable frequency of *LRRK2* variants in the Latin American research consortium on the genetics of Parkinson's disease (LARGE-PD), a case of ancestry. *NPJ Parkinsons Dis.* 2017;3:19.
18. Hatano T, Funayama M, Kubo SI, et al. Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease. *Neurobiol Aging.* 2014;35(11):2656.e17-2656.e23.
19. Tomiyama H, Li Y, Funayama M, et al. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. *Mov Disord.* 2006;21(8):1102-1108.

20. Funayama M, Hasegawa K, Ohta E, et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. *Ann Neurol.* 2005;57(6):918-921.
21. Okubadejo N, Britton A, Crews C, et al. Analysis of Nigerians with apparently sporadic Parkinson disease for mutations in LRRK2, PRKN and ATXN3. *PLoS One.* 2008;3(10):e3421.
22. Okubadejo NU, Rizig M, Ojo OO, et al. Leucine rich repeat kinase 2 (LRRK2) GLY2019SER mutation is absent in a second cohort of Nigerian Africans with Parkinson disease. *PLoS One.* 2018;13(12):e0207984. Published 2018 Dec 3.
23. Keyser RJ, Lombard D, Veikondis R, Carr J, Bardien S. Analysis of exon dosage using MLPA in South African Parkinson's disease patients. *Neurogenetics.* 2010;11(3):305-312.
24. Bardien S, Marsberg A, Keyser R, et al. LRRK2 G2019S mutation: frequency and haplotype data in South African Parkinson's disease patients. *J Neural Transm (Vienna).* 2010;117(7):847-853.
25. Mahne AC, Carr JA, Bardien S, Schutte CM. Clinical findings and genetic screening for copy number variation mutations in a cohort of South African patients with Parkinson's disease. *S Afr Med J.* 2016;106(6):10.7196/SAMJ.2016.v106i6.10340.
26. Bardien S, Blanckenberg J, van der Merwe L, Farrer MJ, Ross OA. Patient-control association study of the Leucine-Rich repeat kinase 2 (LRRK2) gene in South African Parkinson's disease patients. *Mov Disord.* 2013;28(14):2039-2040.
27. du Toit N, van Coller R, Anderson DG, Carr J, Bardien S. Frequency of the LRRK2 G2019S mutation in South African patients with Parkinson's disease. *Neurogenetics.* 2019;20(4):215-218.

28. Yonova-Doing E, Atadzhanov M, Quadri M, et al. Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease. *Parkinsonism Relat Disord.* 2012;18(5):567-571.
29. Cilia R, Sironi F, Akpalu A, et al. Screening LRRK2 gene mutations in patients with Parkinson's disease in Ghana. *J Neurol.* 2012;259(3):569-570.
30. Oluwole OG, Kuivaniemi H, Abrahams S, et al. Targeted next-generation sequencing identifies novel variants in candidate genes for Parkinson's disease in Black South African and Nigerian patients. *BMC Med Genet.* 2020;21(1):23.
31. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry.* 1992;55(3):181-4.
32. KASP User guide. LGC Limited. KASP genotyping chemistry User guide and manual. Available at: <https://biosearch-cdn.azureedge.net/assetsv6/KASP-genotyping-chemistry-User-guide.pdf>
33. Landrum MJ, Chitipiralla S, Brown GR, et al. ClinVar: improvements to accessing data. *Nucleic Acids Res.* 2020;48(D1):D835-D844.
34. Trinh J, Zeldenrust FMJ, Huang J, et al. Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. *Mov Disord.* 2018;33(12):1857-1870.
35. Bandres-Ciga S, Diez-Fairen M, Kim JJ, Singleton AB. Genetics of Parkinson's disease: An introspection of its journey towards precision medicine. *Neurobiol Dis.* 2020 Apr;137:104782.